Systemic treatment of a patient with relapsed and refractory extranodal NK/T‐cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
- 3 August 2018
- journal article
- letter
- Published by Wiley in Hematological Oncology
- Vol. 36 (4) , 713-714
Abstract
Key message: Targeting CD‐38‐positive ENKL cells with daratumumab might be a promising new treatment option. Systemic administration of daratumumab may be active against intracerebral manifestations of CD‐38‐positive ENKL. Serial EBV‐monitoring in ENKL is a usefool tool for diagnosis, response assessment and detection of relapse.Keywords
This publication has 9 references indexed in Scilit:
- Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of diseaseAnnals of Oncology, 2017
- CD38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapyEuropean Journal of Haematology, 2017
- PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginaseBlood, 2017
- Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell LymphomaNew England Journal of Medicine, 2016
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015
- CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal typeAnnals of Hematology, 2015
- SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study GroupBlood, 2012
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group StudyJournal of Clinical Oncology, 2011
- Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009The Lancet Oncology, 2009